Robert Dimeff, MD
Sports Medicine · Dallas, TXNPI 1003870718
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $83,616 of the $105,804 with a category attached, or 79.0%. 9 manufacturers reported payments, led by Pacira Therapeutics, Inc. at 41.9% of the total. Reporting peaked in 2019 at $75,177 and has fallen 94.1% since, to $4,407 in 2025. Among sports medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $729.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pacira Therapeutics, Inc.$44K
- Ferring Pharmaceuticals Inc.$34K
- Sanofi-aventis U.S. LLC$16K
- Orthogenrx Inc.$10K
- Pacira Pharmaceuticals Incorporated$713
- Stryker$142
- plus $173 from 3 others
Across 3 payments — averaging $7083.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$21K
What the payments were for
- Consulting fees$11,68511%
- Speaking & faculty fees$83,61679%
- Travel & lodging$7,4507%
- Food & beverage$3,0523%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pacira Therapeutics, Inc. | 57 | $44,326 |
| Ferring Pharmaceuticals Inc. | 71 | $34,497 |
| Sanofi-aventis U.S. LLC | 4 | $15,954 |
| Orthogenrx Inc. | 1 | $10,000 |
| Pacira Pharmaceuticals Incorporated | 7 | $713 |
| Stryker | 1 | $142 |
| Pylant Medical | 1 | $127 |
| Johnson & Johnson | 2 | $28 |
| ERMI LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zilretta$44,050
- EUFLEXXA$33,284
- GenVisc 850$10,000
- SYNVISC-ONE$6,765
- NO PRODUCT DISCUSSED$4,920
- Iovera$615
- TRITANIUM$142
- NOCDURNA$125
How this compares
$105,804 in reported general payments places this provider in the 95th percentile of 437 sports medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitroglycerin PatchNitroglycerin | 23 | $862 |
| Celecoxib | 22 | $298 |
| Meloxicam | 42 | $147 |
| Tramadol Hcl | 16 | $55 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Dallas
- Robert ScheinbergDallas$2.2M
- Kelechi OkorohaDallas$297K
- Todd MoenDallas$219K
- Don BufordDallas$80K
- Daniel CooperDallas$74K
- Robert BurgmeierDallas$60K
- Mahmoud KhairDallas$59K
- Dheeraj YalamanchiliDallas$54K
- Karim MeijerDallas$38K
- Mark MullerDallas$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.